8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
DexCom reports 11% third-quarter revenue growth and raises 2026 guidance
Filed with the SEC on · Summarized by InvestorsBot
DexCom reported third-quarter 2026 revenue of $1.344 billion for the period ended September 30, up 11% year over year, with GAAP diluted earnings of $0.72 per share and GAAP operating income of $327.2 million. The company raised its 2026 revenue guidance to $5.20 billion-$5.25 billion, expects approximately 24% non-GAAP operating margin, and authorized up to $1.0 billion in share repurchases; it held $1.82 billion in cash, cash equivalents and marketable securities at quarter-end.